[1] 吴惠惠, 彭春霞, 卫群, 等.白细胞介素37与动脉粥样硬化关系的研究进展[J].中国动脉硬化杂志, 2018, 26(2):213-216. [2] ZHAO J, ZHANG S F, SHI Y, et al. Effects of urotensin Ⅱ and its specific receptor antagonist urantide on rat vascular smooth muscle cells[J]. Bosn J Basic Med Sci, 2013, 13(2):78-83. [3] DIEGO B, ANTONIO L, PIETRO C, et al. Urantide conformation and interaction with the Urotensin-Ⅱreceptor[J]. Archiv Der Pharmazie, 2014, 347(3):185-192. [4] HOSEINI Z, SEPAHVAND F, RASHIDI B, et al. NLRP3 inflammasome:Its regulation andinvolvement in atherosclerosis[J]. J Cell Physiol, 2018, 233(3):2116-2132. [5] ZHANG SS, ZOU J, LI PY, et al. Curcumin Protects against atherosclerosis in apolipoprotein E-knockout mice by inhibiting toll-like receptor 4 expression[J]. J Agric Food Chem, 2018, 66(2):449-456. [6] YANG L, LIU JL, QI GY. Mechanism of the effect of saikosaponin on atherosclerosis in vitro is based on the MAPK signaling pathway[J]. Mol Med Rep, 2017, 16(6):8868-8874. [7] OH J, RIEK A E, ZHANG R M, et al. Deletion of JNK2 prevents vitamin-D-deficiency-induced hypertension and atherosclerosis in mice[J]. J Steroid Biochem Mol Biol,2018, 177:179-186. [8] ZHAO J, YU Q X, KONG W, et al. The urotensin Ⅱ receptor antagonist, urantide, protects against atherosclerosis in rats[J]. Exp Ther Med, 2013, 5(6):1765-1769. [9] ZHAO J, XIE L D, SONG C J, et al. Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats[J]. Exp Ther Med, 2014, 7(6):1647-1652. [10] HUANG Z Y, YANG P Y, AIMOFTI MR, et al. Comparative analysis of the proteome of leftventricular heart of arteriosclerosis in rat[J]. Life Sci, 2004, 75(26):3103-3115. [11] JIAO Y B, RUI Y C, LI T J, et al. Expression of pro-inflammatory and anti-inflammatory cytokines in brain of atherosclerotic rats and effects of Ginkgo biloba extract[J]. Acta Pharmacol Sin, 2005, 26(7):835-839. [12] 牛镜磊, 张钲. 新型炎症标志物在动脉粥样硬化中的研究进展[J]. 中国循环杂志, 2017, 32(5):516-517. [13] MARANHAO R C, LEITE JR A C. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease[J]. Curr Pharm Des, 2015, 21(9):1196-1204. [14] ZHAO D, TONG L, ZHANG L, et al. Tanshinone Ⅱ A stabilizes vulnerable plaques bysuppressing RAGE signaling and NF-kappaB activation in apolipoprotein-E-deficient mice[J].Mol Med Rep, 2016, 14(6):4983-4990. [15] UMEBASHI K, TOKITO A, YAMAMOTO M, et al. Interleukin-33 induces interleukin-8 expression via JNK/c-Jun/AP-1 pathway in human umbilical vein endothelial cells[J]. PLoS One, 2018, 13(1):e0191659. [16] NISHI M, YONESU K, TAGAWA H, et al. A Novel and highly potent urotensin Ⅱ Receptor antagonist inhibits urotensin Ⅱ-induced pressure response in mice[J]. J Cardiovasc Pharmacol, 2019, 73(1):15-21. [17] SVISTUNOV A A, TARASOV V V, SHAKHMARDANOVA S A, et al. Urotensin Ⅱ:molecular mechanisms of biological activity[J]. Curr Protein Pept Sci, 2018, 19(9):924-934. [18] 汤伟. 辛伐他汀治疗冠心病合并高脂血症34例副作用分析[J]. 中国实用医药, 2013, 8(2):51-52. [19] CHEN ZD, XU JH, YE Y, et al. Urotensin Ⅱ inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling[J]. J Cell Mol Med, 2014, 18(5):852-862. [20] GENG J, YANG C C, WANG B J, et al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway[J]. Biomed Pharmacother, 2018, 97:941-947. [21] KWOK K H M, CHENG K K Y, HOO R L C, et al. Adipose-specific inactivation of JNK alleviates atherosclerosis in apoE-deficient mice[J]. Clin Sci (Lond), 2016, 130(22):2087-2100. |